At the time of writing, Apogee Therapeutics Inc [APGE] stock is trading at $78.95, up 0.89%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The APGE shares have gain 4.21% over the last week, with a monthly amount glided 2.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stephens started tracking the stock with Overweight rating on December 17, 2025, and set its price target to $95. On December 10, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $103 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $109 on November 03, 2025. Mizuho initiated its recommendation with an Outperform and recommended $105 as its price target on October 21, 2025. RBC Capital Mkts started tracking with an Outperform rating for this stock on September 25, 2025, and assigned it a price target of $60. In a note dated July 07, 2025, BTIG Research reiterated a Buy rating on this stock and boosted its target price from $100 to $115.
For the past year, the stock price of Apogee Therapeutics Inc fluctuated between $26.20 and $80.99. Currently, Wall Street analysts expect the stock to reach $107.33 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $78.95 at the most recent close of the market. An investor can expect a potential return of 35.95% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.35 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 76.75 points at the first support level, and at 74.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 80.74, and for the 2nd resistance point, it is at 82.54.
Ratios To Look Out For
It is important to note that Apogee Therapeutics Inc [NASDAQ:APGE] has a current ratio of 15.86. Further, the Quick Ratio stands at 15.86, while the Cash Ratio is 3.17.
Transactions by insiders
Recent insider trading involved CARL DAMBKOWSKI, Officer, that happened on Jan 07 ’26 when 35200.0 shares were purchased. Chief Financial Officer, Henderson Jane completed a deal on Jan 02 ’26 to sell 6000.0 shares. Meanwhile, Chief Financial Officer Henderson Jane sold 2000.0 shares on Jan 06 ’26.
